Paris

• An Open-Label Phase 2a Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Dementia with Lewy Bodies (DLB) Ended
  2024-511446-39-00 4 2024-08-02 Dementia with Lewy Bodies (DLB)
• GuARD: GR1014 cutaneous gel Against Radiation Dermatitis Ended
  2023-508728-36-00 4 2024-07-26 Radiation-induced dermatitis (radiodermatitis)
• Effect of botulinum toxin on hamstring contracture and the occurrence of cyclops syndrome following anterior cruciate ligament reconstructio … Ended
  2023-509193-32-01 4 2024-07-18 Cyclops syndrome
• A Study of Lorigerlimab with Docetaxel or Docetaxel Alone in Participants with Metastatic Castration-Resistant Prostate Cancer Ended
  2022-502982-49-00 4 2024-07-15 Metastatic Castration-Resistant Prostate Cancer
• Open-label Extension of Vericiguat in Pediatric Participants with Heart Failure due to Left Ventricular Systolic Dysfunction Ended
  2023-506210-40-00 5 2024-06-28 Heart Failure due to Systemic Left Ventricular Systolic Dysfunction
• A study to test long-term treatment with spesolimab in people with a skin condition disease called hidradenitis suppurativa (HS) who took pa … Ended
  2023-508377-82-00 10 2024-06-27 Hidradenitis Suppurativa (HS)
• A study to evaluate the efficacy and safety of subcutaneous amlitelimab in participants aged 12 years and older with moderate-to-severe atop … Ended
  2023-506558-20-00 5 2024-06-26 Dermatitis atopic
• A Proof-of-Concept study to assess the efficacy, safety and tolerability of itepekimab (anti-IL-33 mAb) in participants with non-cystic fibr … Ended
  2023-508663-70-00 4 2024-06-18 Bronchiectasis
• Clinical trial of V940 and pembrolizumab in people with resectable locally advanced cutaneous squamous cell carcinoma Ended
  2023-505712-37-00 10 2024-06-06 The participants must have a histologically confirmed diagnosis of res
• A Two-Part Study to Assess the Effectiveness, Safety, and Blood Levels of Repeat Doses of Inhaled ETD001 in People with Cystic Fibrosis Ended
  2023-504092-25-00 4 2024-06-04 Cystic Fibrosis
• Long-term Safety and Efficacy Study of Fitusiran in Patients with Hemophilia A or B, with or without Inhibitory Antibodies to Factor VIII or … Ended
  2023-508884-59-00 5 2024-06-03 Hemophilia A or Hemophilia B
• A study to evaluate the efficacy and safety of subcutaneous amlitelimab monotherapy compared with placebo in participants aged 12 years and … Ended
  2022-501196-41-00 5 2024-05-29 Dermatitis atopic
• [68Ga]Ga-PentixaFor-PET imaging for staging of marginal zone lymphoma Ended
  2022-500918-25-00 5 2024-05-20 Marginal Zone Lymphoma
• A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation Ended
  2023-503223-26-00 9 2024-05-07 Advanced Solid Tumors Harboring a KRASG12C Mutation
• EFFICACY AND SAFETY OF GSK4527226 [AL101] IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE Ended
  2023-505083-11-01 4 2024-05-07 Alzheimer's Disease
• First-in-Human Study of TAK-280 in Participants With Unresectable Locally Advanced or Metastatic Cancer Ended
  2023-504012-16-00 7 2024-04-29 Unresectable Locally Advanced or Metastatic Cancer
• Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) Ended
  2022-502899-23-00 5 2024-04-23 Hepatic Encephalopathy (OHE)
• A Multicenter, Randomized, Double-Blind, Comparative, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous Imipenem/Cilastatin-X … Ended
  2022-501952-27-00 5 2024-04-19 Hospital-acquired bacterial pneumonia (HABP), including ventilated HAB
• Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer Ended
  2023-504630-22-00 7 2024-04-19 Non-Small Cell Lung Cancer
• "TOPOLOGY" : A phase II study to evaluate the efficacy and toxicities of PLX038, in patients with locally advanced or metastatic triple-nega … Ended
  2022-501507-27-00 4 2024-04-17 Advanced or metastatic triple-negative breast cancer
• A Phase 2 Trial of BDC-1001 as Single Agent and in Combination with Pertuzumab in Subjects with Human Epidermal Growth Factor Receptor 2–Pos … Ended
  2023-506038-65-00 4 2024-04-15 HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2–POSITIVE METASTATIC BREAST CA
• A Phase 2b, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Dose Finding study to evaluate the Efficacy, Safety, Pharmacokinet … Ended
  2023-505414-15-00 4 2024-04-10 Dermatitis, Atopic
• A Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Choroidal Neovascularization Secondary to Pathologic Myopia Ended
  2023-506707-25-00 5 2024-04-09 Choroidal neovascularization secondary to pathologic myopia
• Atezolizumab plus RP1 oncolytic immunotherapy in the NeoAdjuvant setting of Triple-Negative Breast Cancer Ended
  2022-502311-12-00 4 2024-04-05 Patients with early-stage Triple Negative Breast Cancer

Showing 1,897–1,920 of 2,286 trials